Skip to content
Screener

Emergent Biosolutions EBS Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
$0
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$0
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
CorMedix logo
CorMedixCRMD
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV

Other financials

Income statement

See full
Revenue$234.3M+66.3%
Gross profit$137.2M+85.4%
Operating income-$125.1M-7,919%
Net income-$180.2M-1,402%
EPS (diluted)-$3.49-1,486%

Balance sheet

See full
Cash & equivalents$140.9M-48.0%
Total debt$588.2M-13.0%
Total equity$341.4M-36.3%
Total assets$1.1B-21.2%

Cash flow

See full
Operating cash flow$56.1M-47.3%
CapEx$2.1M-27.6%
Free cash flow$54.0M-47.8%

Valuation

See full
Market cap$248.16M-47.4%
Enterprise value$695.46M-19.5%
P/S0.3×-0.2×

Profitability

See full
Gross margin55.9%+2.4pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin11.9%

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.7×+0.5×
Current ratio5.4×-0.2×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.

Filed
Aug 5, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001367644-26-000082
Line itemJune 30, 2026December 31, 2025
Total liabilities775.4796.0
Stockholders' equity:
Preferred stock, $0.001 par value per share; 15.0 shares authorized, no shares issued or outstanding
Common stock, $0.001 par value per share; 200.0 shares authorized, 61.9 and 60.9 shares issued; 51.3 and 52.1 shares outstanding, respectively0.10.1
Treasury stock, at cost, 10.7 and 8.7 common shares, respectively(270.5)(252.6)
Additional paid-in capital951.8942.4
Accumulated other comprehensive loss, net(6.8)(7.5)
Accumulated deficit(333.2)(159.8)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Emergent Biosolutions's common stock, par value (in dollars per share)?
Emergent Biosolutions (EBS) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
How has Emergent Biosolutions's common stock, par value (in dollars per share) changed year-over-year?
Emergent Biosolutions's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Emergent Biosolutions's common stock, par value (in dollars per share)?
Over 5 years (2020 to 2025), Emergent Biosolutions's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
What does common stock, par value (in dollars per share) mean?
Common stock, par value (in dollars per share)

Ask your AI about Emergent Biosolutions's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude